JP6876631B2 - 白金化合物、組成物及びその使用 - Google Patents

白金化合物、組成物及びその使用 Download PDF

Info

Publication number
JP6876631B2
JP6876631B2 JP2017566743A JP2017566743A JP6876631B2 JP 6876631 B2 JP6876631 B2 JP 6876631B2 JP 2017566743 A JP2017566743 A JP 2017566743A JP 2017566743 A JP2017566743 A JP 2017566743A JP 6876631 B2 JP6876631 B2 JP 6876631B2
Authority
JP
Japan
Prior art keywords
compound
dose
acid
group
cisplatin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2017566743A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018518510A (ja
Inventor
ジー． アラゴバ、ロシッツァ
ジー． アラゴバ、ロシッツァ
ティ． ビロドー、マーク
ティ． ビロドー、マーク
ウースター、リチャード
モロー、ブノワ
ウェイレン、ケリー
ラムスタック、ジェイ．マイケル
エヌ． ロックウッド、ダニエル
エヌ． ロックウッド、ダニエル
ス、パトリック イム
ス、パトリック イム
シン、サクジート
イェン、ツン ピー． アウ
イェン、ツン ピー． アウ
ルムラン、チャールズ−アンドレ
エム． カスター、リンダ
エム． カスター、リンダ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Placon Therapeutics inc
Original Assignee
Placon Therapeutics inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Placon Therapeutics inc filed Critical Placon Therapeutics inc
Publication of JP2018518510A publication Critical patent/JP2018518510A/ja
Priority to JP2021074407A priority Critical patent/JP7223053B2/ja
Application granted granted Critical
Publication of JP6876631B2 publication Critical patent/JP6876631B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
JP2017566743A 2015-06-23 2016-06-22 白金化合物、組成物及びその使用 Expired - Fee Related JP6876631B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021074407A JP7223053B2 (ja) 2015-06-23 2021-04-26 白金化合物、組成物及びその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562183403P 2015-06-23 2015-06-23
US62/183,403 2015-06-23
US201562268666P 2015-12-17 2015-12-17
US62/268,666 2015-12-17
PCT/US2016/038699 WO2016209918A1 (en) 2015-06-23 2016-06-22 Platinum compounds, compositions, and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021074407A Division JP7223053B2 (ja) 2015-06-23 2021-04-26 白金化合物、組成物及びその使用

Publications (2)

Publication Number Publication Date
JP2018518510A JP2018518510A (ja) 2018-07-12
JP6876631B2 true JP6876631B2 (ja) 2021-05-26

Family

ID=57586683

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017566743A Expired - Fee Related JP6876631B2 (ja) 2015-06-23 2016-06-22 白金化合物、組成物及びその使用
JP2021074407A Active JP7223053B2 (ja) 2015-06-23 2021-04-26 白金化合物、組成物及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021074407A Active JP7223053B2 (ja) 2015-06-23 2021-04-26 白金化合物、組成物及びその使用

Country Status (4)

Country Link
US (2) US10342801B2 (https=)
EP (1) EP3313392B1 (https=)
JP (2) JP6876631B2 (https=)
WO (1) WO2016209918A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX377528B (es) 2015-12-09 2025-03-10 Univ Wien Med Compuestos de platino funcionalizados con monomaleimida para la terapia del cáncer.
CA3062369A1 (en) 2017-05-05 2018-11-08 Intezyne Technologies, Inc. Manufacture of trans-[tetrachlorobis(1h-indazole)ruthenate (iii)] and compositions thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008001101A2 (en) * 2006-06-29 2008-01-03 Astex Therapeutics Limited Pharmaceutical combinations
WO2013033430A1 (en) * 2011-09-02 2013-03-07 Wake Forest School Of Medicine Targeted delivery and prodrug designs for platinum-acridine anti-cancer compounds and methods thereof
WO2014100417A1 (en) 2012-12-19 2014-06-26 Blend Therapeutics, Inc. Compounds, compositions, and methods for the treatment of cancers
US10011622B2 (en) 2013-12-31 2018-07-03 Placon Therapeutics, Inc. Compounds, compositions, and methods for the treatment of cancers
EP3797768A1 (en) 2014-06-23 2021-03-31 Placon Therapeutics, Inc. Maleimide-functionalised platinum for use in the treatment of cancer

Also Published As

Publication number Publication date
EP3313392A4 (en) 2019-02-27
US20190350940A1 (en) 2019-11-21
EP3313392B1 (en) 2020-09-16
US10342801B2 (en) 2019-07-09
EP3313392A1 (en) 2018-05-02
WO2016209918A1 (en) 2016-12-29
US20180243318A1 (en) 2018-08-30
JP2018518510A (ja) 2018-07-12
JP7223053B2 (ja) 2023-02-15
JP2021119164A (ja) 2021-08-12

Similar Documents

Publication Publication Date Title
ES2435452T3 (es) Métodos y composiciones para tratar un cáncer recurrente
AU2019388843B2 (en) An Aurora A kinase inhibitor for use in the treatment of neuroblastoma
JP6659764B2 (ja) 白金化合物、組成物、及びそれらの使用
TWI607754B (zh) 醫藥組合
US20230277519A1 (en) Irak4 degraders and uses thereof
JP2017061512A (ja) 液体配合剤
JP7223053B2 (ja) 白金化合物、組成物及びその使用
US20220323433A2 (en) Clinical regimen for treating myelodysplastic syndrome with phosphatase inhibitor
JP2023107900A (ja) 標的治療剤
CA2876371A1 (en) Prophylactic and/or therapeutic agent for mild cognitive impairment
US20220241294A1 (en) Bisfluoroalkyl-1,4-benzodiazepinone compounds for treating notch-activated breast cancer
CN116490177B (zh) 通路调节剂、含其的药物组合物、其用途和采用其的治疗方法
JP2021521107A (ja) ｔｅｒｔ−ブタノールレベルを低下させた医薬組成物
WO2020123496A1 (en) Novel approach for treatment of cancer using immunomodulation
JP2024519342A (ja) 自己免疫性、同種免疫性、炎症性、及びミトコンドリア性の状態を治療するための組成物、ならびにその使用
Yang et al. HS-10296–a novel third generation EGFR tyrosine kinase inhibitor: results of the first-in-human phase 1 trial in patients with previously treated EGFR mutant advanced non-small-cell lung cancer
US20250120970A1 (en) Pharmaceutical composition including phthalazinone derivative for co-administration with anticancer drug
CN119522109A (zh) 用于钙调磷酸酶抑制剂的间歇性给药的组合物
TW202440116A (zh) 組合療法
WO2025232873A1 (zh) 多西他赛白蛋白组合物治疗胃癌或胃食管结合部癌的用途
WO2025103408A1 (zh) 治疗alk阳性或ros1阳性的非小细胞肺癌的方法
CN120603579A (zh) 新型溶液
WO2023143611A1 (zh) 一种治疗癌症的方法
Markham Anti-androgen (L02BB04)
EP4729061A1 (en) Use of akt inhibitor in preparation of drug for preventing or treating breast cancer

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190614

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200512

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200730

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201111

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210224

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210326

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210426

R150 Certificate of patent or registration of utility model

Ref document number: 6876631

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE

Ref document number: 6876631

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees